Market reactionShares fell 26% on Nov 2.
Precigen sells PAPZIMEOS, the first FDA-approved treatment for adults with recurrent respiratory papillomatosis, and develops other AdenoVerse immunotherapies such as PRGN-2009.
Precigen's case rests on PAPZIMEOS, which received full FDA approval in August 2025 for adults with recurrent respiratory papillomatosis. Second-quarter revenue was $53.1 million, more than double the first quarter, and Precigen was profitable. Payers cover nearly all insured U.S. lives, and FDA granted seven years of exclusivity. Customers pay 127 days after sale, so receivables rose $68.0 million in the first half and cash and investments fell to $38.7 million. Precigen expects cash flow break-even by year-end.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: PAPZIMEOS sales keep growing
Do PAPZIMEOS sales keep growing while cash stops falling?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
PAPZIMEOS sales more than doubled to $53.1 million, making Precigen profitable
PAPZIMEOS launches into an orphan RRP market with no approved competition; the thesis turns on whether revenue scales to cash-flow breakeven by end of 2026
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Breast and gynecologic cancers, Other cancers, Lung and respiratory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
3 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.